In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
Roche acquires ADC rights from Innovent for lung cancer treatment in $1 billion deal Roche strengthens its global foothold in ...
Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...
Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...
Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for ...
Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...
China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to ...
Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...
Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback